diabetes Archive — Page 3 of 17
-
August 2, 2023
VUMC receives $28 million to lead national study of COVID-diabetes link
Researchers at Vanderbilt University Medical Center have received a four-year, $28 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to study the relationship between COVID-19 and diabetes. -
August 2, 2023
The urgency of research
Griffin Rodgers, MD, director of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, described the urgency of the nation’s diabetes epidemic July 26 during a symposium of the NIDDK Medical Student Research Program in Diabetes and Obesity hosted by Vanderbilt University. -
July 10, 2023
Gannon receives career achievement award for islet biology research
Vanderbilt's Maureen Gannon, PhD, received the Paul Lacy Medal Award, the highest honor given by the Midwest Islet Club in recognition of meritorious career achievement in the field of islet biology. -
June 13, 2023
Maternal diet influences postnatal diabetes risk
Studies in a primate animal model suggest that islet hyperfunction — which in humans is associated with increased fat mass and Type 2 diabetes — is programmed in offspring by a maternal Western-style diet during pregnancy. -
May 23, 2023
Diabetes Day celebrates 50 years of achievement, spotlights current investigations
Vanderbilt Diabetes Day, an annual event hosted by the now-named Vanderbilt Diabetes Research and Training Center (DRTC). The event spotlights the work of researchers, and this year also celebrated the 50-year anniversary of the DRTC. -
May 19, 2023
Gorden honored with Vanderbilt Diabetes Center Lifetime Achievement Award
Phillip Gorden, MD, a Vanderbilt University undergraduate and School of Medicine alumnus, was recently honored with the Vanderbilt Diabetes Center Lifetime Achievement Award, during the recent Diabetes Day sponsored by the Vanderbilt Diabetes Research and Training Center and the Irwin B. Eskind Endowed Symposium. -
May 8, 2023
Diabetes drugs associated with fewer adverse cardiac events in older veterans: study
Vanderbilt research finds that GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease.